Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database - PubMed
7 hours ago
- #Anti-CD20 Antibodies
- #Pharmacovigilance
- #Ocular Toxicity
- Anti-CD20 monoclonal antibodies, including rituximab, ofatumumab, ocrelizumab, obinutuzumab, and ublituximab, were analyzed for ocular adverse events (OAEs) using FAERS data from 2014 to 2024.
- OAEs were most reported with rituximab (67.44%), followed by ocrelizumab (21.68%) and ofatumumab (8.88%), with females accounting for 74.25% of cases and median age of 61 years.
- All five anti-CD20 antibodies showed signals for ocular infections, indicating a class effect, and over half of OAEs occurred within 15 days of treatment initiation.
- Ofatumumab was linked to increased blepharospasm risk in multiple sclerosis patients (ROR=1.62), suggesting effects on ocular motor control in CNS disease.
- Rituximab was associated with elevated dyschromatopsia risk in multiple sclerosis patients (ROR=18.90), indicating possible optic nerve or retinal pathway dysfunction related to immune-mediated demyelination.